Form 4: Compass Pathways Director Ekaterina Malievskaia Executes Stock Sales Under 10b5-1 Plan

Ekaterina Malievskaia, a director at Compass Pathways plc, executed multiple sales of ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Ekaterina Malievskaia, a director at Compass Pathways plc, reported the sale of ordinary shares on April 16 and 17, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
• On April 16, 2024, 23,880 shares were sold at a weighted average price of $8.5289, with prices ranging from $8.17 to $8.83.
• On the same day, her spouse, George Jay Goldsmith, sold 23,881 shares at the same weighted average price.
• On April 17, 2024, 10,850 shares were sold at a weighted average price of $8.7841, with prices ranging from $8.70 to $8.88.
• Her spouse also sold 10,850 shares on the same day at the same weighted average price.
• Following these transactions, Dr. Malievskaia directly owns 3,973,400 shares and indirectly owns 3,975,673 shares through her spouse.
• Dr. Malievskaia and Mr. Goldsmith disclaim beneficial ownership of each other's shares.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the specified ranges upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by a company insider under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather reflects routine financial activity.

Management Comments

• Dr. Malievskaia and Mr. Goldsmith expressly disclaim beneficial ownership of each other's shares in the Issuer.

Industry Context

This filing is a routine disclosure of stock sales by a company insider, which is common in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, including those in the biotechnology sector like Compass Pathways.
• Companies like Mind Medicine (MNMD) and Atai Life Sciences (ATAI), which are also in the psychedelic medicine space, often have similar filings related to insider transactions.
• The use of Rule 10b5-1 trading plans is a standard practice among executives and directors to manage their stock sales in compliance with securities laws.

Stakeholder Impact

• The stock sales by a director and their spouse could have a minor impact on shareholder sentiment, but the existence of a pre-arranged trading plan mitigates concerns about insider trading.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates